Medicare Part D coverage · methocarbamol · RxCUI 2691000
methocarbamol 1000 MG Oral Tablet [Tanlor]
Per the CMS 2026 Part D formulary file, methocarbamol 1000 MG Oral Tablet [Tanlor] is covered by 27 Medicare Part D plans (0.5% of enrollable products), averaging Tier 1.8, with prior authorization required on 0% of covering formularies.
- 0.5%
- Plan coverage
- 27
- Plans covering
- T1.8
- Avg tier
- 0%
- Prior auth required
What the CMS Formulary Data Shows for methocarbamol 1000 MG Oral Tablet [Tanlor]
Per the CMS 2026 Part D formulary file, methocarbamol 1000 MG Oral Tablet [Tanlor] (RxNorm concept RXCUI 2691000, generic name methocarbamol) appears on 5 distinct formulary files spanning 27 Medicare Part D plan offerings - 0.5% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 2, with a cross-plan average of Tier 1.8.
Real-world access to methocarbamol 1000 MG Oral Tablet [Tanlor] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 1,036,252 Part D beneficiaries filled methocarbamol 1000 MG Oral Tablet [Tanlor] in 2023, with total plan-and-beneficiary spending of $32,564,136 and an average per-beneficiary annual cost of $31.42. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry methocarbamol 1000 MG Oral Tablet [Tanlor] today.
Coverage Details
- Formularies covering
- 5
- Plans covering
- 27
- Coverage rate
- 0.5%
- Tier range
- Tier 1 – Tier 2
- Average tier
- Tier 2, Generic
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 0% of formularies
2023 Medicare Spending
- Beneficiaries
- 1,036,252
- Total spending
- $32,564,136
- Avg per beneficiary
- $31.42
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering methocarbamol 1000 MG Oral Tablet [Tanlor]
27 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| CareAdvantage (HMO D-SNP) | SAN Mateo Health Commission | T1 | No | $0 | CA |
| Prominence Plus (HMO) | Prominence Healthfirst | T2 | No | $0 | NV |
| Prominence Plus (HMO) | Prominence Healthfirst | T2 | No | $0 | NV |
| Prominence Dual (HMO D-SNP) | Prominence Healthfirst | T2 | No | $0 | NV |
| Prominence Dual (HMO D-SNP) | Prominence Healthfirst | T2 | No | $0 | NV |
| Prominence Giveback (HMO) | Prominence Healthfirst | T2 | No | $0 | NV |
| Prominence Plus (HMO) | Prominence Healthfirst OF Florida Inc | T2 | No | $0 | FL |
| Prominence Giveback (HMO) | Prominence Healthfirst OF Florida Inc | T2 | No | $0 | FL |
| Prominence Plus (HMO) | Prominence Healthfirst OF Texas | T2 | No | $0 | TX |
| Prominence Plus (HMO) | Prominence Healthfirst OF Texas | T2 | No | $0 | TX |
| Prominence Dual (HMO D-SNP) | Prominence Healthfirst OF Texas | T2 | No | $0 | TX |
| Prominence Extra Help (HMO) | Prominence Healthfirst OF Texas | T2 | No | $0 | TX |
| Prominence Beyond (HMO) | Prominence Healthfirst OF Texas | T2 | No | $0 | TX |
| Prominence Giveback (HMO) | Prominence Healthfirst OF Texas | T2 | No | $0 | TX |
| Prominence Giveback (HMO) | Prominence Healthfirst OF Texas | T2 | No | $0 | TX |
| Prominence Dual (HMO D-SNP) | Prominence Healthfirst OF Texas | T2 | No | $0 | TX |
| Prominence Beyond (HMO-POS) | Prominence Healthfirst OF Texas | T2 | No | $0 | TX |
| Prominence Dual (HMO D-SNP) | Prominence Healthfirst OF Florida Inc | T2 | No | $0 | FL |
| Prominence Diabetes and Heart Giveback (HMO C-SNP) | Prominence Healthfirst | T2 | No | $0 | NV |
| Prominence Diabetes and Heart Giveback (HMO C-SNP) | Prominence Healthfirst OF Florida Inc | T2 | No | $0 | FL |
Show the next 7 plans
| Prominence Diabetes and Heart Giveback (HMO C-SNP) | Prominence Healthfirst OF Texas | T2 | No | $0 | TX |
| Prominence Diabetes and Heart Care Plus (HMO C-SNP) | Prominence Healthfirst OF Texas | T2 | No | $0 | TX |
| Prominence Diabetes and Heart Giveback (HMO C-SNP) | Prominence Healthfirst OF Texas | T2 | No | $0 | TX |
| Prominence Extra Help (HMO) | Prominence Healthfirst | T2 | No | $4.20 | NV |
| Prominence Extra Help (HMO) | Prominence Healthfirst OF Florida Inc | T2 | No | $4.80 | FL |
| Prominence Extra Help (HMO) | Prominence Healthfirst OF Texas | T2 | No | $4.80 | TX |
| Prominence Extra Help (HMO) | Prominence Healthfirst | T2 | No | $9.50 | NV |
Frequently Asked Questions
Is methocarbamol 1000 MG Oral Tablet [Tanlor] covered by Medicare Part D?
Yes, methocarbamol 1000 MG Oral Tablet [Tanlor] is covered by 27 Medicare Part D plans (0.5% of all Part D formularies).
What tier is methocarbamol 1000 MG Oral Tablet [Tanlor] on Medicare Part D plans?
methocarbamol 1000 MG Oral Tablet [Tanlor] averages Tier 1.8 across Part D plans, ranging from Tier 1 to Tier 2.
Does methocarbamol 1000 MG Oral Tablet [Tanlor] require prior authorization?
0% of Part D formularies require prior authorization for methocarbamol 1000 MG Oral Tablet [Tanlor]. Step therapy: 0%. Quantity limits: 0%.
How much does Medicare spend on methocarbamol 1000 MG Oral Tablet [Tanlor]?
In 2023, total Medicare Part D spending on methocarbamol 1000 MG Oral Tablet [Tanlor] was $32,564,136, covering 1,036,252 beneficiaries. The average spend per beneficiary was $31.42.
Read our methodology - how this data is sourced, computed, and verified.
Nationwide similar Part D drugs
Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.
Closest average formulary tier
- 2 ML methotrexate 25 MG/ML Injection T1.8
- 24 HR bupropion hydrochloride 150 MG Extended Release Oral Tablet T1.8
- hydrocortisone 25 MG/ML Topical Cream T1.8
- ketorolac tromethamine 5 MG/ML Ophthalmic Solution T1.8
- lidocaine hydrochloride 20 MG/ML Mucous Membrane Topical Solution T1.8
- mirtazapine 7.5 MG Oral Tablet T1.8
Similar prior-authorization rate
- metronidazole 10 MG/ML Topical Cream [Noritate] 0% PA
- 24 HR minocycline 40 MG Extended Release Oral Capsule [Emrosi] 0% PA
- buspirone hydrochloride 10 MG Oral Capsule [Bucapsol] 0% PA
- diflunisal 375 MG Oral Tablet [Dolobid] 0% PA
- hydrocortisone 1 MG/ML Oral Solution [Khindivi] 0% PA
- indomethacin 50 MG Rectal Suppository [Indocin] 0% PA